You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 157 No. 3, 10 FEBRUARY 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex Virus Infection in Women

A Multicenter, Double-Blind, Placebo-Controlled Trial

Gregory J. Mertz, MD; Mark O. Loveless, MD; Myron J. Levin, MD; Stephen J. Kraus, MD; Sandra L. Fowler, MD; Diane Goade, MD; Stephen K. Tyring, MD, PhD

Arch Intern Med. 1997;157(3):343-349.


Abstract

Objective
To evaluate the efficacy and safety of oral famciclovir in the suppression of genital herpes.

Methods
In this randomized, double-blind, placebo-controlled trial that was performed at 11 university and 9 private ambulatory care referral centers, 375 women who were 18 years of age or older and had a history of 6 or more episodes of genital herpes during 12 of the last 24 months in the absence of suppressive therapy were treated for 4 months with oral famciclovir, 125 mg once daily or twice daily, 250 mg once daily or twice daily, 500 mg once daily, or placebo. The primary outcome measures included the time to first clinically and virologically confirmed recurrences, and safety as measured by clinical laboratory tests and adverse experiences.

Results
The median time to first recurrence was 82 days in the placebo group, 114 days in those receiving famciclovir, 125 mg once daily, and more than 120 days in the other treatment groups. When compared with placebo recipients, the time to the first clinical recurrence was significantly prolonged in subjects who received famciclovir, 125 mg twice daily (hazard ratio, 1.8; 95% confidence interval, 1.0-3.0; P=.03), and in those who received famciclovir, 250 mg twice daily (hazard ratio, 3.6; 95% confidence interval, 1.9-6.9; P<.001). Treatment was well tolerated, and there was no evidence of emergence of resistance during or after suppressive famciclovir therapy.

Conclusions
Oral famciclovir, 250 mg, given twice daily for 4 months is an effective, well-tolerated treatment for the suppression of genital herpes in women with frequent recurrences, but single daily doses produced less complete suppression of genital herpes.

Arch Intern Med. 1997;157:343-349



Author Affiliations

From the Department of Internal Medicine, School of Medicine, University of New Mexico Health Sciences Center, Albuquerque (Drs Mertz and Goade); the Department of Medicine, Oregon Health Sciences University, Portland (Dr Loveless); the Department of Pediatrics, University of Colorado School of Medicine, Denver (Dr Levin); Georgia Clinical Research Center, Atlanta (Dr Kraus); the Department of Pediatrics, Medical University of South Carolina, Charleston (Dr Fowler); and the University of Texas Medical Branch at Galveston (Dr Tyring). Members of the Collaborative Famciclovir Genital Herpes Research Group are listed on page 346.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Treatment of Herpes Simplex Infections: An Evidence-Based Review
Cernik et al.
Arch Intern Med 2008;168:1137-1144.
ABSTRACT | FULL TEXT  

Patient satisfaction with care for genital herpes: insights from a global survey
Patrick et al.
Sex. Transm. Infect. 2004;80:192-197.
ABSTRACT | FULL TEXT  

Genital Herpes
Kimberlin and Rouse
NEJM 2004;350:1970-1977.
FULL TEXT  

Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study
Schacker et al.
Antimicrob. Agents Chemother. 2002;46:3243-3248.
ABSTRACT | FULL TEXT  

Effects of Antiviral Usage on Transmission Dynamics of Herpes Simplex Virus Type 1 and on Antiviral Resistance: Predictions of Mathematical Models
Lipsitch et al.
Antimicrob. Agents Chemother. 2000;44:2824-2835.
ABSTRACT | FULL TEXT  

Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology
Ashley and Wald
Clin. Microbiol. Rev. 1999;12:1-8.
ABSTRACT | FULL TEXT  

Update on drugs for herpes zoster and genital herpes
DTB 1998;36:77-79.
ABSTRACT | FULL TEXT  

Oral Famciclovir for the Suppression of Recurrent Genital Herpes: A Randomized Controlled Trial
Diaz-Mitoma et al.
JAMA 1998;280:887-892.
ABSTRACT | FULL TEXT  

FAMCICLOVIR FOR RECURRENT GENITAL HERPES SIMPLEX INFECTIONS IN WOMEN
JWatch General 1997;1997:4-4.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.